Please be aware that the information provided is a summary of select releases made to the ASX, as evaluated and interpreted by ASX Briefs. It is important to thoroughly read the entire original release before forming an opinion, rather than relying solely on the brief overview presented here. ASX Briefs is not associated with the ASX. ASX Briefs is an experimental AI project incorporating chatGPT, and as such, does not guarantee the accuracy of the information provided.
CardieX receives FDA 510(k) clearance for the CONNEQT Pulse, a first-of-its-kind multi-use vascular biometric monitor.
The Pulse measures both brachial and central blood pressure, arterial waveform analysis, and other unique vascular biomarkers – targeting home health, remote patient monitoring, and decentralized clinical trial markets.
Commercial availability of the Pulse is expected in Q3 of this year, addressing new and significant global markets for cardiovascular health monitoring and vascular disease management.